Can Vancomycin or Cefepime Cause Hyperbilirubinemia?
Yes, both vancomycin and cefepime can cause hyperbilirubinemia, though through different mechanisms and with different clinical significance.
Cefepime and Hyperbilirubinemia
Cefepime can cause elevated total bilirubin as a documented adverse effect. According to the FDA drug label, increased total bilirubin occurred in less than 1% but greater than 0.1% of patients in clinical trials 1. This represents a direct hepatotoxic effect rather than a displacement phenomenon.
Key Clinical Points for Cefepime:
- The bilirubin elevation is typically part of a broader pattern of liver enzyme abnormalities
- Also causes increased ALT (2.8%), AST (2.4%), and alkaline phosphatase 1
- Monitor liver function tests if prolonged therapy is planned, especially in patients with renal or hepatic impairment 1
Vancomycin and Hyperbilirubinemia
Vancomycin causes hyperbilirubinemia through two distinct mechanisms: direct hepatotoxicity and bilirubin-albumin displacement.
Direct Hepatotoxicity:
A 2024 case series found vancomycin-induced liver injury occurred in 0.37% of 4,562 patients treated 2. The critical finding is that 9 of 17 patients (52.94%) with liver injury also had abnormal bilirubin levels 2. The hepatotoxicity pattern shows:
- Onset: 2-12 days after starting vancomycin (mean 4.53 days)
- 94.1% of cases occurred within 7 days 2
- All patients had elevated AST/ALT, with 52.9% also showing bilirubin abnormalities 2
- Most cases (88.24%) were grade 1 (mild) liver injury 2
- No correlation between vancomycin blood concentration and severity of liver injury 2
Bilirubin-Albumin Displacement:
Vancomycin displaces bilirubin from albumin binding sites, increasing unbound (free) bilirubin without necessarily raising total bilirubin 3, 4. This is particularly dangerous in:
- Neonates and premature infants (risk of kernicterus)
- Patients receiving multiple albumin-bound drugs simultaneously
- The displacement effect is unpredictable when vancomycin is combined with other drugs 4
A 2021 case report demonstrated that high-dose ampicillin caused marked increases in unbound bilirubin, which resolved when vancomycin was substituted, suggesting vancomycin has less displacement effect than some other antibiotics 3. However, the 1991 study showed vancomycin combinations with cefotaxime produced unpredictable effects on bilirubin binding 4.
Clinical Monitoring Recommendations
For both drugs, monitor liver function tests including total and direct bilirubin:
Baseline Assessment:
- Obtain baseline ALT, AST, alkaline phosphatase, total bilirubin, and direct bilirubin before starting therapy
- If direct bilirubin is elevated, calculate the conjugated fraction (should be >35% in drug-induced liver injury vs. <20-30% in Gilbert's syndrome) 5
During Therapy:
- For vancomycin: Check liver function tests within 3-7 days of initiation (when 94% of hepatotoxicity cases manifest) 2
- For cefepime: Monitor if therapy extends beyond 2 weeks or in patients with baseline liver disease
- If ALT/AST rise ≥3× baseline with bilirubin ≥2× ULN, interrupt the drug and evaluate for alternative causes 5, 6
Special Populations:
- Neonates receiving vancomycin: Monitor unbound bilirubin if available, not just total bilirubin 3
- Patients on multiple albumin-bound drugs: Consider the unpredictable combined displacement effects 4
- Patients with renal impairment: Both drugs require dose adjustment; failure to adjust increases toxicity risk 1
Common Pitfalls to Avoid
- Don't assume normal total bilirubin excludes vancomycin toxicity in neonates—unbound bilirubin may be dangerously elevated 3
- Don't attribute isolated hyperbilirubinemia to drug effect without checking direct/conjugated fraction—may be Gilbert's syndrome 5
- Don't ignore vancomycin hepatotoxicity because blood levels are therapeutic—no correlation exists between concentration and liver injury 2
- Don't continue either drug if bilirubin doubles with elevated transaminases—this signals significant hepatotoxicity requiring drug interruption 5, 6